EI
CCCC icon

Ethic Inc’s C4 Therapeutics CCCC Stock Holding History

Ethic Inc’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,131
Closed -$26.6K – 1373
2026
Q1 		$26.6K Sell
10,131
-147
-1% -$346 ﹤0.01% 1227
2025
Q4 		$19.6K Sell
10,278
-230
-2% -$545 ﹤0.01% 1206
2025
Q3 		$23.3K Sell
10,508
-4,656
-31% -$11.2K ﹤0.01% 1187
2025
Q2 		$21.2K Buy
+15,164
New +$22.1K ﹤0.01% 1205

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ethic Inc's CCCC Position: Q2 2026 in Review

Ethic Inc sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 10,131 shares — an estimated $26.6K sold.

Ethic Inc first reported a position in CCCC in Q2 2025 and held it in 4 quarters. The position peaked at $26.6K in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Ethic Inc reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ethic Inc sold 10,131 C4 Therapeutics shares in Q2 2026, an estimated $26.6K.
  • Ethic Inc first reported a position in C4 Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ethic Inc's C4 Therapeutics position peaked at $26.6K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.